Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
- Leukemia-Lymphoma, Adult T-Cell
- Hodgkin Disease
- Non-Small Cell Lung Cancer
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- National Cancer Institute (NCI)
- Enrolment target
- 500
- Started
- 11 April 2016
- Main results due
- 1 December 2030
- Study sites
- 1
- Registry updated
- 28 September 2026
Can you take part?
- Ages 18 years to 120 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
* INCLUSION CRITERIA: 1. Diagnosis of cancer, a premalignant/neoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant/neoplastic condition 2. Age \>=18 years of age 3. ECOG performance status of 0-3. 5\. Ability and willingness of subject to provide informed consent Additional inclusion criteria pertinent only for participants undergoing apheresis 1. Hemoglobin \>= 8 mg/dL and platelet count \> 75 K/microL 2. Weight \>= 48 kg 3. Central line in place or adequate venous access EXCLUSION CRITERIA: 1. Active concomitant medical or psychological illnesses that may increase the risk to the subject. 2. Inability to provide informed consent 3. Pregnant or breastfeeding women
What this study is about
In the sponsor’s own words, from the registry.
Background:
Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.
Objective:
To better understand the biology of malignancies and why certain cancers respond differently to treatment.
Eligibility:
Adults at least 18 years old with cancer or a pre-cancerous condition.
Design:
Participants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.
Participants will send tissue blocks or slides from their original tumor biopsy.
At least once, participants will have a medical history, physical exam, and blood and urine tests.
Participants may have the following tests. They may have them more than once:
Apheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.
Bone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.
Piece of cancer tissue taken by a needle and syringe.
Computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.
A small piece of skin removed.
Participants will be contacted by phone once a year to find out how they are doing.
Study sites(1)
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT02682667. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me